Alan Joslyn

Alan Joslyn discloses dealings in 3 companies, chiefly Penwest Pharmaceuticals Co, Synergy Pharmaceuticals, Inc. and Oragenics Inc. In total, 22 filings cover trades dated from 23 December 2005 to 25 March 2019.

On the open market, the record shows 1 purchase and 11 sales worth €1.0M. The amount is not disclosed for 1 filing. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 1 share grant and 9 option exercises. In 2019 alone, the filings show 1 purchase and no sales.

Most recently, on 27 March 2019, the filings show an open-market purchase in Oragenics Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.